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A B S T R A C T
The global increases in life expectancy and population have resulted in a growing ageing population and with it a
growing number of people living with age-related neurodegenerative conditions and dementia, shifting focus
towards methods of prevention, with lifestyle approaches such as nutrition representing a promising avenue for
further development.
This overview summarises the main themes discussed during the 3rd Symposium on “Nutrition for the Ageing
Brain: Moving Towards Clinical Applications” held in Madrid in August 2018, enlarged with the current state of
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T
knowledge on how nutrition influences healthy ageing and gives recommendations regarding how the critical
field of nutrition and neurodegeneration research should move forward into the future.
Specific nutrients are discussed as well as the impact of multi-nutrient and whole diet approaches, showing
particular promise to combatting the growing burden of age-related cognitive decline. The emergence of new
avenues for exploring the role of diet in healthy ageing, such as the impact of the gut microbiome and devel-
opment of new techniques (imaging measures of brain metabolism, metabolomics, biomarkers) are enabling
researchers to approach finding answers to these questions. But the translation of these findings into clinical and
public health contexts remains an obstacle due to significant shortcomings in nutrition research or pressure on
the scientific community to communicate recommendations to the general public in a convincing and accessible
way. Some promising programs exist but further investigation to improve our understanding of the mechanisms
by which nutrition can improve brain health across the human lifespan is still required.
1. Introduction
The global increases in life expectancy and population have resulted
in a growing ageing population and with it a growing number of people
living with age-related neurodegenerative conditions and dementia.
Age-related neurodegenerative conditions have an enormous societal
and emotional cost. The prevalence of dementia worldwide is suspected
to be as many as 50 million cases2, with prevalence estimated to be
between 2% and 4% by 65 years, increasing to 15% at 80 years of age3 .
In Europe, it is estimated that approximately 10 million people are
affected, with costs of dementia projected to exceed €250bn by 2030
(Cimler et al., 2019). In the absence of effective pharmacological
treatment to curtail or reverse the mechanisms underlying age-related
cognitive decline, it is necessary to shift focus towards methods of
prevention, with lifestyle approaches representing a promising avenue
for further development.
The link between nutrition and cognitive decline has been the focus
of ILSI Europe’s events on ‘Nutrition for the Ageing Brain’ since the first
successful meeting took place in 2014. ILSI Europe’s events on
‘Nutrition for the Ageing Brain’ provide a forum for discussion of
complex issues relating to nutrition and brain ageing science, bringing
together experts from areas of food science, nutrition, developmental
ageing, and cognitive science. These events have resulted in high
quality and impact peer-reviewed publications (Miquel et al., 2018;
Vauzour et al., 2017). Previous events have focused on the mechanisms
of ageing and their interactions with nutrients (Miquel et al., 2018;
Vauzour et al., 2017). The focus of the 2018 symposium held in Madrid
has shifted towards clinical and applicable aspects of what we know so
far regarding the impact of nutrition on maintaining brain health with
age. This overview summarises the main themes discussed during this
most recent ILSI Europe event, enlarged with the current state of
knowledge on how nutrition influences healthy ageing. Topics dis-
cussed include biomarkers of nutrition, the role of the gut microbiome,
new avenues for research, and recommendations regarding how the
critical field of nutrition and neurodegeneration research should move
forward into the future.
2. Nutrition for healthy ageing
The brain undergoes neural development until approximately the
age of 30 years (Lebel and Beaulieu, 2011; Sowell et al., 2003; Westlye
et al., 2010), after which a slow process of atrophy takes place, with
clinical signs of neurodegeneration typically not occurring until older
age. This trajectory is proposed to be determined by a complex inter-
play of genetic, endogenous and environmental factors (Livingston
et al., 2017). The typically slow nature of this process allows for a
significant window of opportunity for preventive intervention strate-
gies. Nutrition has been identified as one promising avenue reducing
the risk for age-related pathologies such as age-related
neurodegeneration and dementia.
Nutritional epidemiology has suggested a protective role of healthy
diets and of several candidate nutrients for brain aging outcomes.
Existing evidence suggests that some nutrients or food ingredients, in
particular specific vitamins, flavonoids and long chain ω-3 fatty acids
have a potential to beneficially affect cognitive function (Samieri, 2018;
Scarmeas et al., 2018). Beyond a focus on specific nutrients, the most
optimal preventative avenues are suspected to be based on multi-nu-
trient approaches, as suggested by findings from the Three City ob-
servational study (Amadieu et al., 2017) and other cohort studies (Berti
et al., 2015; Bowman et al., 2012; Gu et al., 2016; Lehtisalo et al., 2019;
Olde Rikkert et al., 2015; Soininen et al., 2017), whole diet approaches,
as well as multi-domain approaches incorporating changes to nutrition
amongst other lifestyle factors such as exercise (Lehtisalo et al., 2019;
Ngandu et al., 2015; Scarmeas et al., 2018). Indeed, several recent
observational and intervention studies have incorporated approaches of
specific nutrients, such as the VITACOG trial (Oulhaj et al., 2016) which
focused on the efficacy of B vitamins to lower biomarkers related to
cognitive decline including homocysteine, combinations of nutrients,
such as the LipiDiDiet (Soininen et al., 2017), whole diet approaches,
such as with the HELIAD study (Anastasiou et al., 2018) which in-
vestigate adherence to a Mediterranean dietary pattern and brain
health. These multi-nutrient approaches highlight specific nutrients
impacting brain ageing.
2.1. Specific nutrients
2.1.1. B-Vitamins
Studies in the USA and in Europe have found that higher intakes of
B vitamins, particularly folates but not B12, were associated with lower
risk of dementia or Alzheimer’s disease (AD); e.g. the Baltimore
Longitudinal Study of Aging (Corrada et al., 2005), and the Three City
study (Lefevre-Arbogast et al., 2016). The Three City study was a
longitudinal population-based study which focused on associations
between the risk of age-related cognitive decline and dementia and
vascular factors in a total of 9294 older adults aged 65–79 years
(Antoniak et al., 2003). In addition to assessment of vascular risk fac-
tors, this study also involved extensive dietary, cognitive, and labora-
tory investigations. Notably, results from this study indicated that
higher intakes of B vitamins, particularly folates but not B12, were
associated with lower dementia risk (Lefevre-Arbogast et al., 2016).
Further evidence suggests that combination of low folates and low B12
relates to higher circulating levels of homocysteine, such that plasma
total homocysteine is sensitive and reliable biomarker of folate and
vitamin B12 status (Refsum et al., 2004). Raised plasma homocysteine
has itself been associated in prospective studies with increased risk of
cognitive decline and dementia (Smith and Refsum, 2016; Smith et al.,
2018), brain atrophy (Smith and Refsum, 2016), and AD pathology
(Hooshmand et al., 2013). However, direct relationships between levels
of folate and B12 and brain health are less consistent in the literature
and yet to be firmly established (Smith, 2008). To further investigate
the association between these B vitamins, homocysteine and cognitive
2 World Alzheimer Report 2018.
3 World Alzheimer Report 2015: The Global Impact of Dementia.
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decline, the VITACOG study recruited 270 community-dwelling sub-
jects> 70 years old with mild cognitive impairment (MCI) and ran-
domised participants to either a daily placebo or tablet containing
0.8 mg folic acid, 0.5mg B12, and 20mg B6 over two years (Smith
et al., 2010). Following treatment, the degree of brain atrophy as
measured using structural magnetic resonance imaging (MRI) was re-
duced by 30% in the group receiving the B vitamins. There was further
attenuation of atrophy in key grey matter regions including the medial
temporal lobes in the active treatment group, with regional grey matter
loss of 0.6% compared to 5.2% in the placebo group (Douaud et al.,
2013). Regarding the association with homocysteine, total brain
atrophy in the placebo group doubled across the levels of baseline
homocysteine, whereas in the active treatment group there was no re-
lation between homocysteine at baseline and atrophy, such that sub-
jects within the top quartile of homocysteine levels showed a 53%
slowing of the rate of brain atrophy (Smith et al., 2010). Furthermore,
subjects receiving B vitamins showed a slower rate of decline in epi-
sodic memory, semantic memory and global cognition as measured by
the Mini-Mental State Examination (MMSE), but only in subjects with
baseline homocysteine levels above the median (> 11 μmol/L), and
improvements in clinical and functional outcomes occurred in subjects
with higher baseline homocysteine levels (> 13μmol/L) (de Jager
et al., 2012). These findings suggested that the disease mechanisms
underlying MCI and subsequent cognitive and clinical aspects could be
modified by B vitamins, in particular for those with elevated levels of
homocysteine (Smith and Refsum, 2017). Other trials in which B vita-
mins were administered have also shown beneficial effects on cogni-
tion, but some trials have not shown benefit; possible reasons for these
discrepancies have been discussed (McCaddon and Miller, 2015; Smith
and Refsum, 2016; Smith et al., 2018). In particular, a meta-analysis
(Clarke et al., 2014) claimed that there was no beneficial effect of B
vitamins on ‘cognitive ageing’ but this analysis is difficult to interpret
since cognition was only tested on one occasion in 74% of the partici-
pants and so cognitive decline over time could not be assessed in these
subjects. One reason why some B vitamin trials appear to have failed
was revealed in the VITACOG trial, where it was found that only those
participants with a good omega-3 fatty acids status benefitted from B
vitamin treatment (see Section 2.2).
2.1.2. Other vitamins and nutrients
Other vitamins and nutrients have been identified as potential
candidates for improving brain ageing however with far less weight and
consistency of supporting evidence. For example, evidence suggests
that a deficiency in vitamin D (25(OH)D<25 nmol/L (10 ng/mL)) is
related to risk of dementia (Feart et al., 2017; Jayedi et al., 2018), al-
though null findings have also been reported in two large cohorts, the
Framingham Heart Study (Karakis et al., 2016) and the Uppsala
Longitudinal Study of Adult men (Olsson et al., 2017). In addition, vi-
tamin E, specifically γ-tocopherol (but not α-tocopherol) has been as-
sociated with lower levels of AD pathology in the human brain (Morris
et al., 2015a), however there still remain very few biomarker studies on
this nutrient and its role in brain health remains controversial
(Scarmeas et al., 2018). Likewise, studies on carotenoids have been
generally limited to dietary questionnaires to assess exposure (Cho
et al., 2018; Li et al., 2012). Even if plasma carotenoids were found to
significantly relate to lower dementia risk (Feart et al., 2015), further
biomarker investigations are again rare and some investigations haven’t
found a link with risk of cognitive change. For example, the Nurse’s
health study (Kang and Grodstein, 2008) found no association of
plasma carotenoids with cognitive change.
Many trials suffer from insufficient samples sizes and duration,
which may contribute to the inconsistency in findings. A recent sys-
tematic review of 38 trials of nutrient supplementation which included
omega-3 fatty acids, B vitamins, vitamin D and carotenoids, concluded
that no evidence-based recommendations can be made for the efficacy
of over the counter vitamin supplements to protect against cognitive
decline in cognitively healthy adults or those diagnosed with MCI
(Butler et al., 2018), but this review did not take into account the
analysis of subgroups that was shown to be crucial in the VITACOG trial
(see above).
2.1.3. Omega-3 fatty acids
Omega-3 fatty acids have received considerable attention in the
context of nutrition and ageing particularly regarding their possible role
in reducing the risk of age-related cognitive decline. Indeed, observa-
tional studies such as the Three City Study showed that higher blood
levels of the long-chain omega-3 fatty acid eicosapentaenoic acid (EPA)
were associated with lower dementia risk and less atrophy of the medial
temporal lobe (Samieri et al., 2008, 2012) (whereas blood levels of
docosahexaenoic acid (DHA) did not reach a significant association
with dementia outcomes in these studies). However, with regards to
pathological age-related decline specifically, there have been findings
of higher blood levels of DHA to be associated with lower dementia risk
(Zhang et al., 2016). A meta-analysis showed that observational studies
support a favourable association between intake/blood levels of DHA
(alone or combined with EPA) with memory function in older adults
with mild memory complaints (Yurko-Mauro et al., 2015).
But randomised-controlled trials (RCT) failed so far to show positive
effects of omega-3 fatty acids supplementation on cognitive perfor-
mance in cognitively healthy older subjects (van de Rest et al., 2008),
or on cognitive decline in elderly people with memory complaints
(Multidomain Alzheimer Preventive Trial (MAPT) (Andrieu et al.,
2017)). The DHA dose used in the MAPT (800mg/day) is below the
maximum recommended daily intake and even higher doses (above 1 g)
showed negative results on cognitive outcomes in trials for MCI and
mild AD probably because the brain pathology is already well advanced
in those patients (Yassine and Schneider, 2017). Therefore omega-3
supplementation might better be tested for prevention purposes in pa-
tients with early dementia (prodromal stages) in trials with larger
sample size and for longer periods to ensure that the intervention has a
chance for success. Indeed, findings from a previous meta-analysis have
hinted that the positive effects of omega-3 supplementation on cogni-
tive performance could be limited to specific cognitive domains in
milder cognitive impairment in the absence of dementia (Mazereeuw
et al., 2012).
Such inconsistency in findings could in part be due to the challenges
relating to measuring habitual intake based on biomarkers of nutrients
not consumed on a daily basis (i.e. marine long-chain omega-3 fatty
acids) using a single blood draw; and in part to factors such as large
variability in composition of bioactives within the same type of food
source; and individual differences in rates of nutrient metabolism.
Another possible reason for inconsistency is that omega-3 fatty acids
may need to interact with other nutrients in order to have a beneficial
effect; for example, there is evidence of interaction with B vitamins, as
discussed thereafter.
2.2. Multi-nutrient interventions
Beyond the impact of specific nutrients working in isolation to im-
prove health, more attention is now being directed towards identifying
combinations of specific nutrients to protect against cognitive decline.
Indeed, combinations of nutrients, specifically between fatty acids, vi-
tamins A, E, and D, and carotenoids, have been identified as a candidate
pattern of nutrients relating to long-term risk of dementia in healthy
older adults (Amadieu et al., 2017). Specifically, a pattern consisting of
low levels of vitamin D, carotenoids and polyunsaturated fatty acids in
conjunction with high levels of saturated fats was associated with a 3.7
fold higher risk of dementia onset – twice the risk conferred by carrying
the APOEε4 genotype (Amadieu et al., 2017). However, these findings
require further replication, as previous studies have been pre-
dominantly cross-sectional and limited, and the role of B vitamins in
combination with other nutrients has yet to be adequately investigated.
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Post-hoc results from the VITACOG study showed that levels of total
plasma omega-3 fatty acids modulated the impact of the B vitamin
treatment with respect to slowing brain atrophy (Jerneren et al., 2015)
and cognitive and clinical outcomes (Oulhaj et al., 2016), suggesting
that indeed the effect of B vitamins on brain health may depend on
larger dietary patterns involving other key nutrients. Likewise, the
beneficial effect of omega-3 fatty acids may depend upon B vitamin
status. The OmegAD trial, a single-centre randomized control trial
which primarily investigated the effect of supplementing omega-3 fatty
acids on measures of cognition in 204 patients with mild to moderate
AD, found in a recent post-hoc analysis that omega-3 fatty acids im-
proved cognition in AD only in a subgroup with good B vitamin status
as revealed by low levels of the marker homocysteine despite not
finding an impact on slowing cognitive decline across the whole cohort
(Jerneren et al., 2019), suggesting that an interaction between con-
currently higher omega-3 fatty acids and B vitamins could be more
critical for preventing cognitive decline.
The LipiDiDiet (Soininen et al., 2017) is one of the very few existing
interventions involving a multi-nutrient approach. This double-blind,
placebo-controlled multicentre trial investigated the impact of a com-
bined supplement Fortasyn Connect (Souvenaid®) consisting of 11 nu-
trients linked previously to brain health (uridine monophosphate,
choline, phospholipids, EPA, DHA, vitamins E, C, B6, B9, B12, and
Selenium), in 311 adults with prodromal AD (Soininen et al., 2017)
taken over 24 months. Although the study found that in the control
population the cognitive decline was less than expected and thus the
primary endpoint (a Neuropsychological Test Battery) was in-
adequately powered, the intervention produced significant benefits on
clinical measures on cognitive performance and everyday function.
Regarding biomarkers, the intervention resulted in significantly re-
duced brain atrophy, particularly in hippocampal and ventricular re-
gions, and further evidence for effects mediated via biomarkers such as
homocysteine and DHA status. The benefit of this intervention ap-
peared further to be modified depending on how early in the disease
process treatment had been initiated. These results suggest that this
particular combined nutrient intervention could slow disease progres-
sion when taken over an extended period of time. Despite these pro-
mising findings, optimal combinations of specific nutrients that stop
disease progression or which are more effective at the dementia stage of
the disease have yet to be determined.
2.3. Whole diet approaches
Due to complex interactions between nutrients and foods, the use of
a whole-diet approach may provide advantages in understanding the
role of diet and cognitive impairment. Thus, adherence to dietary pat-
terns has been evaluated in many investigations. The candidate nu-
trients for prolonging brain health with age are found abundantly in
certain whole-diet approaches. In particular, the Mediterranean diet,
which has been the most extensively studied dietary pattern in the
context of brain ageing as well as other health conditions such as heart
disease and cancer (Dinu et al., 2018; Trichopoulou, 2004). The Med-
iterranean diet originates from the food cultures around the Medi-
terranean Basin (Davis et al., 2015). Although several variants of the
Mediterranean diet exist, it is generally characterized by abundance of
plant foods including fruits (an after-dinner dessert or a between-meal
snack), vegetables (as either main or side dish), bread and other forms
of cereals, legumes, nuts, and seeds. Olive oil is the principal source of
fat. The Mediterranean diet also includes moderate amounts of dairy
products (principally the fermented ones, i.e. cheese and yogurt), low to
moderate amounts of fish and poultry, red meat in low amounts and
wine, consumed modestly, normally with meals. Evidence from long-
itudinal studies and clinical trials indicates that adherence to the
Mediterranean diet is associated with slower rates of decline in cogni-
tive performance and with lower risk for cognitive impairment
(Scarmeas et al., 2018; van den Brink et al., 2019).
One of the most prevalent studies investigating the impact of a
Mediterranean style diet on health outcomes was the PREDIMED
(Prevención con Dieta Mediterránea) study (Estruch et al., 2018),
which was a multicentre trial conducted in Spain focusing mainly on
older adults (55–80 years) who had high cardiovascular risk from May
2005 to December 2010. Participants were allocated to either a Medi-
terranean-style diet with extra-virgin olive oil, a Mediterranean-style
diet with mixed nuts, or a control diet that focused on limiting overall
dietary fat intake. Particularly, one finding from this study relevant to
the current discussion was that a Mediterranean diet with extra-virgin
olive oil was associated with higher scores of global cognitive perfor-
mance following the 6.5 year nutritional intervention (Martinez-
Lapiscina et al., 2013). Similarly, the NU-AGE study (“New dietary
strategies addressing the specific needs of elderly population for
healthy ageing in Europe”) (Santoro et al., 2014) was a 12-month
dietary intervention conducted between May 2011 until April 2016
which sought to modulate the deleterious effects of chronic in-
flammation and other age-related disease processes in a total of 1250
older adults (aged 65–79) by implementing a personally-tailored
Mediterranean-style diet intervention. The study took place in centres
in France, Italy, the United Kingdom, the Netherlands and Poland. Al-
though results relevant to the main objectives of the study are still being
processed, available results show that a higher adherence to the Med-
iterranean diet over the year-long intervention was associated with
statistically significant improvements in overall cognition and measures
of episodic memory compared with participants with lower adherence
(Marseglia et al., 2018), despite a general good uptake of the diet across
the different European regions (Berendsen et al., 2018).
Currently, the HELIAD study is a population-based multidisciplinary
study on the prevalence of ageing-related neuropsychiatric conditions
and the potential associations between diet, lifestyle and cognitive
performance in older adults (Dardiotis et al., 2014). Study participants
were randomly selected from community-dwelling adults over the age
of 65 years from two municipalities in Greece, Larissa (small urban
centre) and Marousi (large urban center). Information pertaining to
demographics, medical history, neurological and psychiatric assess-
ment of the participants, including a comprehensive neuropsycholo-
gical evaluation of all major cognitive domains was collected in addi-
tion to dietary and lifestyle habits, such as sleep, physical activity, and
social interaction. A cross-sectional analysis of the 1864 participants
showed a positive association between adherence to the Mediterranean
diet and a decreased risk for dementia, as well as better cognitive
performance in multiple domains including memory (Anastasiou et al.,
2017). In addition, adherence to a lifestyle index incorporating factors
such as sleep, physical activity, and involvement in activities of daily
living showed higher adherence to these lifestyle factors was related to
better cognitive function (Anastasiou et al., 2018). These findings
suggest that a multi-domain approach incorporating diet alongside
other health-promoting lifestyle factors could optimize beneficial ef-
fects on promotion of cognitive performance and prevention of decline
with age. Indeed, trials such as the FINGER (Finnish Geriatric Inter-
vention Study to Prevent Cognitive Impairment and Disability) study
emerged to investigate the impact of a 24-month multi-domain ap-
proach to preventing cognitive decline in older at-risk individuals
aged> 60 years (Ngandu et al., 2015). The FINGER trial has been the
first large longitudinal randomized control trial which involves a
combination of exercise, diet, cognitive training and management of
vascular risk factors. This trial has produced promising results re-
garding the impact of the multidomain intervention on overall cogni-
tive outcomes compared to the control group, however the individual
impact of each of the intervention components remains to be elucidated
and which lifestyle changes or combination thereof are effective at
delaying cognitive decline.
Despite these promising findings in support of the Mediterranean
diet as a beneficial approach to preventing age-related cognitive de-
cline, the evidence remains limited and further investigation is
E. Flanagan, et al. Ageing Research Reviews 62 (2020) 101079
4
required. In particular, evidence from carefully designed prospective
studies with long follow-up periods and conclusive intervention trials is
needed. Regarding the diet itself, many aspects of the diet such as fluid
intake, timing, distribution of food intake during the day and beha-
viours associated with eating have not yet been evaluated. The me-
chanisms by which this dietary pattern exerts its beneficial effects on
health also remain to be fully elucidated. This is particularly relevant
for populations which may have different genetic and epigenetic var-
iations, gut bacterial diversity, and variation in metabolic status and
exposure to environmental factors, as these aspects could significantly
modulate the impact of dietary interventions on health outcomes. There
is, however, evidence of the possible beneficial effects of the
Mediterranean diet in the USA (Scarmeas et al., 2006) and of a modified
Mediterranean diet, the MIND (Mediterranean-DASH Intervention for
Neurodegenerative Delay) diet (Morris et al., 2015b, c). The MIND diet
combines principles from the Mediterranean diet and the DASH
(Dietary Approaches to Stop Hypertension) diet, aiming at reducing
dementia and a decline in brain health. Importantly, the first clinical
trials designed to test the effects of a 3-year intervention of the MIND
diet on cognitive decline among older subjects are ongoing.
To optimize the impact of these interventions on prevention of age-
related cognitive decline, lifelong environmental and genetic compo-
nents which increase vulnerability to neurodegeneration need to be
further identified and understood, and possibly incorporated as addi-
tional targets in future interventions towards a more personalized ap-
proach to nutrition. Indeed, there is a growing interest in other factors
that could modulate the impact of these interventions, with one of the
most salient being the influence of the gut microbiome on disease
processes related to neurodegeneration, which remains a very open
field. This potential modulating role of the microbiome and its re-
levance to nutrition and the ageing brain will be explored further in the
next section. The exploration of these modulating factors requires ac-
curate methods and models in order to assess efficacy of future inter-
ventions, which will be explored further in the next section.
3. New research avenues
3.1. Microbiome: impact on the ageing brain
Many age-related diseases, including neurodegenerative conditions,
are considered to be the result of a complex interaction of disease
processes involving the immune system, inflammation, and recently the
microbiome. The gut microbiome is the collective genome underlying
the 1013-1014 microorganisms which make up the gastrointestinal mi-
crobiota, predominantly bacteria but also including fungi, viruses, and
other single-celled organisms (Montalban-Arques et al., 2015). The
human gut microbiome is being increasingly recognized as a potent
physiological contributor to health. The structure of the gut micro-
biome varies considerably between individuals, as well as within in-
dividuals over the lifespan, in response to both endogenous and en-
vironmental factors, including host genetics, age, diet, lifestyle and
disease.
With specific regard to age, the gut microbiome undergoes sig-
nificant changes across the lifespan, featuring hallmark characteristics
in the different phases of life (Cani, 2018; Kundu et al., 2017). The
ageing process is characterized by several disease-causing mechanisms
which could be influenced by changes to the gut microbiome. Such
processes include: 1) cellular ageing, including oxidative damage, tel-
omere shortening, advanced glycation end products (AGEs) formations,
damage to DNA; 2) immunosenescence, including changes in adaptive
immunity such as the reduced ability to produce new antibodies and
poor vaccine response, and inflammageing, altered innate immunity,
such as reduced activity of “killer” cells and chronic systemic in-
flammation with elevated IL-6, CRP and TNF-α; 3) changes in body
composition, including reductions in muscle mass and increased adip-
osity; 4) changes in gut physiology, including the type and quality of
intestinal mucin produced, changes in gut permeability, reduced transit
times, increased Helicobacter pylori carriage and small bowel bacterial
overgrowth (SBO); and 5) dysregulation of tryptophan metabolism,
particularly via kynurenine pathways, resulting in levels of bioavailable
serotonin which has been linked to a number of neurodegenerative
conditions including dementia (Ruddick et al., 2006; Schwarcz et al.,
2012), which in turn could be regulated by gut microbiota composition
(Clarke et al., 2013; Desbonnet et al., 2008; Wikoff et al., 2009).
As such, older age is generally associated with an aberrant gastro-
intestinal microbiome profile characterized by modified microbiome
resilience and loss of homeostatic regulation of microbial diversity,
enrichment in pathogenic bacterial species and rearrangements in
saccharolytic and proteolytic microbial populations (Kelly et al., 2015;
Qin and Wade, 2017), with especially a reduction in short-chain fatty
acid (SCFA) producers (Biagi et al., 2017). One of the pioneering studies
in the field, Claesson et al. (Claesson et al., 2012), demonstrated that
the gut microbiota changes in the elderly are closely related to the host
health and residential status. Interestingly however, de la Cuesta-
Zuluaga et al. (2019) demonstrated that the influence of the host’s sex
decreases over the lifespan, such that greater bacterial diversity was
detected in younger women than men but this difference was not sig-
nificant after middle age (de la Cuesta-Zuluaga et al., 2019). Indeed,
while the microbial populations detected in community-dwelling
healthy elderly are overall comparable to those of young adults, elderly
living in long-term residential care and frail elderly bear a distinct,
“more” compromised microbiome signature, with low biodiversity,
underrepresentation of SCFA-producing bacteria and low fecal levels of
SCFAs, possibly contributing to the age-related functional decline.
Biagi et al. (Biagi et al., 2016) reconstructed the longest available
trajectory of the human gut microbiome along ageing, from young
adults up to the extremes of human lifespan, i.e. centenarians and semi-
supercentenarians (persons who reach the age of 105 years). Con-
firming previous findings, the authors observed a core microbiota of
symbiotic bacterial groups (mainly SCFA producers) with diversity and
cumulative abundance decreasing along with age, and an age-related
increasing contribution of opportunistic and allochthonous bacteria.
Interestingly, the gut microbiota of extremely old people showed some
peculiarities, including the presence of microorganisms typical of other
niches (e.g. Mogibacteriaceae, known to be abundant in the periodontal
environment) and the enrichment and/or higher prevalence of health-
associated taxa: Bifidobacterium (well-known probiotics with long his-
tory of use), Akkermansia (recently proposed as next-generation pro-
biotics or live biotherapeutics for the treatment of obesity and related
complications) (Cani and de Vos, 2017; O’Toole et al., 2017) and
Christensenellaceae (whose relative abundance has been found to be
significantly influenced by host genetics (Goodrich et al., 2014)). This
provided the fascinating glimpse of a possible biological print of ageing-
supportive/longevity-adapted microbial communities. Indeed recent
findings suggest that human age can be predicted based on individual
microbial profiles and that such features selected by predictive models
are age-related (Galkin et al., 2018).
From a functional point of view, Rampelli et al. (Rampelli et al.,
2013) found a distinctive microbiome structure in Italian centenarians,
with an overall proteolytic propensity matching the observed altera-
tions in urinary and serum levels of aromatic amino acids and their
metabolites (Collino et al., 2013). It is worth noting that the cen-
tenarian gut metagenome also harboured features that are known to
support longevity in experimental models: i) reduced folate synthesis
and ii) increased biosynthesis of polyamines. The comparison of mi-
crobiota data from Italian centenarians to those from China and Japan
revealed common features, including the decrease in SCFA producers
and the enrichment in pathobionts as well as in health-associated taxa,
which could represent robust, universal signatures of longevity
(Santoro et al., 2018). Of course, it is impossible to know if the health-
associated features of the centenarian microbiome were already present
at a younger age, (re)acquired later on or somewhat related to the
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individual’s past life. Similarly, it remains to be determined whether the
microbial shifts during the human lifetime merely reflect secondary
biological changes or are the result of an adaptive process and con-
tribute to age-related physiological transitions. Promising findings from
animal models emphasize the lifelong value of commensal bacteria (and
derived compounds) to their host (Han et al., 2017) but we are still far
from knowing if these microbiota roles in animal longevity also impact
humans and, above all, if they can be manipulated. In an attempt to
provide answers to at least some of these questions, lifelong long-
itudinal studies or continuation of existing ones to follow microbial
changes within the same individual across life should be promoted.
Future research should also combine metagenomics with other fields,
including meta-transcriptomics and metabolomics, as well as with
“culturomics” and animal models, to improve understanding of the
intricate microbiome-host crosstalk and the relationships between
specific microbial communities and their products and age-dependent
phenotypes.
Even though several questions are still unanswered, overall the
available findings suggest that manipulating the gut microbiome to-
wards a healthy-like/ageing-supportive profile (e.g. through diet, phy-
sical activity, administration of probiotics and/or postbiotics, or even
faecal microbiota transplantation) could be an effective way to activate
major host longevity signalling and promote healthy ageing. In parti-
cular, the growing recognition that microbiota could play a key role in
the functioning of the gut-brain axis could reveal a key role of micro-
biota in promoting brain health with age and preventing neurodegen-
eration. The mechanisms by which microbiota could influence the
functioning of the brain appear to be complex and multidirectional,
involving neural, endocrine and immune pathways. Of particular im-
portance in the context of the role of gut microbiota in supporting brain
function over time is whether these pathways could be modulated via
dietary impacts on gut microbiota, revealing the possibility to curtail
age-related neurodegeneration through dietary changes.
3.2. Prebiotics, probiotics and postbiotics
The growing focus on the human gut microbiome as an avenue to
maintain brain health, has also nurtured interest in prebiotics both as
tools to discern the mechanisms underlying microbiome-gut-brain axis
communication, and as interventions to assist in the treatment of
mental illnesses. According to the latest definition by the International
Scientific Association of Probiotics and Prebiotics (ISAPP), dietary
prebiotics are defined as ‘a substrate that is selectively utilized by host
microorganisms conferring a health benefit' (Gibson et al., 2017). Pre-
biotics include dietary fibers that facilitate the growth of beneficial gut
bacteria and have been suggested to influence neurobiology and be-
havior through an impact on gut microbiota. Regarding specific pre-
biotics, studies involving the commercially available galacto-oligo-
saccharide prebiotic (B-GOS) have shown increased growth of
Bifidobacteria compared to a fructo-oligosaccharide (FOS) prebiotic. In
rodents, this effect is further associated with the prevention of post-
inflammatory anxiety (Savignac et al., 2016) and improvement in
cognitive flexibility (Gronier et al., 2018). In human studies, B-GOS
prebiotics have been shown to increase attentional vigilance to positive
stimuli (Schmidt et al., 2015), similar to antidepressants. The pro-
cognitive effect of the B-GOS prebiotic has now been demonstrated in
schizophrenia patients who display severe cognitive deficits that are not
alleviated by current treatments (Kao et al., 2019b).
The mechanisms of prebiotic actions on the brain remain elusive.
The three main mechanisms that are currently considered to play a role
in communication along the microbiota-gut-brain axis are 1) the im-
mune system, 2) metabolites from the diet that result from bacterial
fermentation, and 3) the vagus nerve connecting the gut to the brain.
One particular suggested mechanism to underpin the central actions of
prebiotics may involve acetate generated from their fermentation by
the enteric bacteria. Acetate has epigenetic effects in the brain and
modulates key glutamate receptors that are integral to neurodevelop-
ment and cognition (Gronier et al., 2018). However, although acetate is
readily absorbed and reaches the brain via the circulation, it is not
solely responsible for the central effects observed after prebiotic in-
gestion (Kao et al., 2019a). Other possible mechanisms, through which
SCFA’s affect the brain, are the modulation of the vagus nerve activity,
and/or through anti-inflammatory effects within the gut. In the latter
instance, certain bacterial metabolites have been proposed to modulate
the gut epigenome and permeability (Qin et al., 2018), which in turn
impacts the infiltration and activity of immune cells as well as the ab-
sorption of bioactives and hormones (Postler and Ghosh, 2017; Qin
et al., 2018). All these factors working individually or in synergy have
the potential to impact on central function (Sarkar et al., 2016). There is
no doubt that bacterial fermentation of prebiotic intake generates
SCFA’s, acetate, propionate and butyrate in the gut, but it is not clear
how they contribute, if at all, to the psychotropic actions of these car-
bohydrates. An improved understanding of the mechanisms underlying
the actions of certain prebiotics will identify pathways that could po-
tentially be more effectively manipulated in order to treat brain dis-
orders at all ages. Furthermore, since prebiotics occur naturally in the
diet, knowing how they affect the brain, both in its healthy and dis-
ordered form, will provide useful information for healthy dietary
choices.
In addition to escalating research into the mechanisms underlying
the psychotropic effects of prebiotics, it is crucial that more human
studies are conducted. Laboratory animals have fixed diets, and so
prebiotic supplementation is more likely to have a robust and re-
producible impact on microbial communities and gut physiology.
Furthermore, replication of the positive cognitive effects seen following
prebiotic intervention in schizophrenia (Kao et al., 2019b) are needed
using other formulations and in clinical trials. These investigations
should also be extended to other cognitive disorders such as dementia,
and natural age-related cognitive decline. In all cases, prebiotics if
proven effective at attenuating psychological symptoms of brain dis-
orders are likely to be used adjunctively rather than on their own. That
is, it is unlikely that manipulating the gut microbiome through the in-
gestion of a prebiotics alone will have an effect on central dysfunctions.
It is more likely that supplements will be used as an additional therapy
to improve brain metabolism and assist it in its response to current
therapies.
Introducing beneficial bacterial species, such as Bifidobacterium bi-
fidum, a probiotic (i.e. a live microorganism that when ingested confers
positive health effects to the host), or adding prebiotics, such as fruc-
tooligosaccharides (FOS) promoting growth and activity of certain
bacterial species are the conventional methods for manipulating the
intestinal microbial community. Advances in high-throughput sequen-
cing and metabolomics, however, have unravelled the importance of
emerging postbiotics, which can be used to directly and specifically
manipulate microbiota function (Wegh et al., 2019). The term “post-
biotics” indicates any soluble factor resulting from the metabolic ac-
tivity of a live bacteria or any released molecule capable of providing
health benefits through a direct or indirect mechanism. There is sub-
stantial evidence to suggest that many health beneficial effects asso-
ciated with the establishment of a symbiotic gut microbiota are pro-
moted by bacterial metabolic by-products, although the role of specific
bioactive compounds and their probiotic effects and how they are
mediated by other metabolites remains to be elucidated and has not yet
been adequately explored in humans. Particularly, there is a focus on
the subgroup of probiotics commonly referred to as ‘psychobiotics’
which have direct influences on neural health via the release of neu-
roactive compounds via the gut-bacteria-brain axis (for review, see
(Oleskin and Shenderov, 2019). Relevant to neurobiology of neurode-
generation and cognitive defects, identification of novel postbiotics and
the pathways responsible for their production may improve mechanistic
understanding of the role that specific probiotics, prebiotics, and
postbiotics have in restoring intestinal microbiota composition and
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associated neuroprotective functions (Mosca et al., 2019; Oleskin and
Shenderov, 2019).
3.3. Improved biomarkers of diet and ageing
Metabolomics is a versatile tool that has many applications in nu-
trition research. Applications are wide ranging and include identifica-
tion of dietary biomarkers, examination of mechanisms through which
diet impacts on health and the study of diet related diseases.
Metabolomics is the measurement of small molecules called metabolites
in biological samples such as urine and blood. The main technologies
used are Nuclear Magnetic Resonance (NMR) and Mass Spectrometry
(MS) based approaches. NMR is a robust, reproducible, quantitative and
high-throughput approach. However, it is not as sensitive as the MS
based approaches. To achieve optimal coverage of the metabolome one
should use multiple platforms.
With respect to the area of dietary biomarkers there is an urgent
need for objective measures of dietary intake to be used in conjunction
with self-reported dietary data. Metabolomic based approaches have
been very successful in identification of new dietary biomarkers and
published examples demonstrate that for certain foods quantitative
analysis of the biomarkers can give an estimation of intake of the
specific food. Furthermore, the work demonstrated good agreement
between the biomarker data and intake as assessed by semi-weighed
food diaries (Gibbons et al., 2017). Other examples of quantitative
biomarkers are also available in the literature (Garcia-Perez et al.,
2017). However, not all dietary biomarkers will deliver quantitative
information with respect to food intake. However, these biomarkers are
still very useful for studying relationships with health and disease. For
example, 22 lipid biomarkers which were related to total dietary fat
intake have previously been identified. From this panel a number of
lipids demonstrated responsiveness to different levels of fat intake in an
intervention study and importantly were related to HOMA-IR, a mea-
sure of insulin resistance. A recent study examining the relationships
between circulating metabolites and cognition and dementia revealed
that 15 metabolites were consistently associated with cognition across
multiple cohorts (van der Lee et al., 2018).
While a number of putative biomarkers for food intake exist in the
literature there is an urgent need to validate these against agreed cri-
teria (Dragsted et al., 2018). Such criteria include biological plausi-
bility, dose response studies and replication. Using these suggested
criteria more work is needed to validate existing markers so that we are
at a stage where we can have biomarkers that assess the major food
groups and obtain a good assessment of dietary intake. In the field of
cognitive health there is a lack of studies examining the relationship
between circulating metabolites and cognitive health. Additionally,
there is a knowledge gap with respect to the impact of cognitive decline
on key metabolic pathways. Future research should investigate the
underlying mechanisms for the observed associations between meta-
bolites and cognition/dementia. Work should also examine if these
metabolites could be used as a signature for prevention/therapeutic
strategies. Furthermore, it would be worth investigating if modulation
of these metabolites could be achieved through an intervention and if
this in turn impacts on cognitive health. Future work should be devoted
to developing biomarkers of food intake that in turn could be used to
examine the relationship between food intake and cognitive health.
Finally, cross collaboration between nutrition scientists and clinicians is
crucial to maximise potential in this area.
Biomarkers of ageing help identify individuals at high risk of pre-
mature ageing. These biomarkers also shorten the period necessary to
test the efficacy of preventive interventions aimed at promoting healthy
ageing. Nine hallmarks of ageing were listed in 2013 (Lopez-Otin et al.,
2013). This prompted a list of molecular, functional, and anthropo-
metric parameters that change with chronological age and which
therefore could be called biomarkers of ageing (Burkle et al., 2015).
However, a single robust, universal, safe, and non-expensive biomarker
of ageing remains to be identified. Although telomere length is dis-
cussed here, there exist other classes of biomarkers such as epigenomics
and proteomics which are beyond the scope of this current review (for a
more comprehensive review, see (Zierer et al., 2015).
Telomere attrition was listed as one the nine hallmarks of ageing
(Lopez-Otin et al., 2013). Telomeres are repeating DNA sequences lo-
cated at chromosomal ends that protect genomic stability. Telomeres
shorten each time a somatic cell divides, and this fostered the use of
telomere length in circulating cells as a biomarker of ageing in many
epidemiologic studies. However, while telomere length is a good
marker for proliferating cells (i.e. microglial cells), its validity for
tracking replicative senescence of organs or tissues rich in post-mitotic
cells (i.e. post-mitotic neurons) is still a matter of debate. Be it as it may,
shorter telomeres are associated with a decreased life expectancy and
increased rates of developing age-related chronic diseases. Focusing on
brain, case-control studies have repeatedly reported that patients with
AD display shorter telomeres compared to controls (Forero et al., 2016)
and a causal link has been suggested through a Mendelian randomi-
zation approach (Zhan et al., 2015). However, the association is less
firmly established in prospective studies on telomere length and cog-
nitive decline (Zhan et al., 2018).
Oxidative stress and inflammation are believed to play a key role in
brain ageing. On the other hand, both inflammation and oxidative
stress also relate to telomere attrition, and observational studies re-
inforced the notion that long-term consumption of antioxidant-rich
foods such as seeds, nuts and whole grains relate to preserved telomeres
(Freitas-Simoes et al., 2018). It follows that sustained consumption of
plant-based foods (i.e. rich in antioxidant and anti-inflammatory com-
pounds) might delay brain ageing by counteracting telomere attrition.
Nevertheless, research on this interplay is still in its infancy. In the
framework of the Finnish Geriatric Intervention Study to Prevent
Cognitive Impairment and Disability (FINGER) trial, conducted in el-
derly people at risk for dementia (Ngandu et al., 2015), the cognitive
benefits from the advice to increase consumption of plant foods as part
of a multi-domain intervention over control (general health advice)
were more pronounced in participants at the bottom tertile of baseline
telomere length of circulating cells (so-called “higher-risk individuals
(Sindi et al., 2017)”). This is a promising finding. However, a tentative
telomere length cut-off point to identify individuals at high risk of
cognitive decline (i.e. those who can obtain the largest cognitive ben-
efits of lifestyle-related interventions) is yet to be established. In addi-
tion, further refining on the influence of age, risk of cognitive decline,
dietary background, duration of supplementation, and type of supple-
mentation (nutrient or bioactive vs food vs dietary pattern; alone vs
multi-nutrient vs multi-domain) is warranted in long-term and ade-
quately powered randomized controlled trials exploring the interplay
between diet, telomeres and cognition. Cognitively healthy participants
with genetic risk factors of AD appear as an ideal population to conduct
such trials.
3.4. Brain metabolism
Brain PET imaging shows that deteriorating brain energy metabo-
lism is a pre-symptomatic problem that increases the risk of AD in older
people, individuals with insulin resistance, carriers of the PSEN1 (pre-
senilin 1) and APOE4 (apolipoprotein E4) genetic mutations, and in
people with a family history of AD (Cunnane et al., 2016). The dete-
rioration of brain energy metabolism is specific to glucose – it does not
affect the brain’s metabolism of ketone bodies in older people
(Castellano et al., 2019), in MCI (Fortier et al., 2019) or in AD itself
(Croteau et al., 2018). This is a crucial observation because it shows
that brain cells having difficulty using glucose can still use ketones as an
alternative energy source, indicating that the neurons are not com-
pletely lost, and also that brain energy rescue by ketones is a potential
strategy to slow down the onset and possibly progression of AD.
Indeed, recent PET studies show that this ‘ketone rescue’ strategy
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could provide benefits to brain metabolism (Fortier et al., 2019). A
ketogenic drink containing medium chain triglyceride (MCT) reduces
the brain energy gap caused by the brain glucose deficit in both MCI
and AD in direct proportion to the plasma ketone level achieved. Fur-
thermore, cognitive outcomes improve in MCI in direct relation to the
plasma ketone level achieved by the MCT drink. This has been de-
monstrated in a 6-month randomized, placebo-controlled trial
(n= 19–20/group; (Fortier et al., 2019). Based on these results, (i)
deteriorating brain energy metabolism appears to be an early and a
central issue in MCI and AD but it is a problem for which a ketogenic
intervention (diet or drink) is a potential solution, (ii) nutritional (or
pharmaceutical) approaches to treating MCI or AD are unlikely to
achieve their full potential unless the problem of the brain energy
(glucose) deficit is addressed. The implication is that a larger trial
adequately powered for cognitive (not metabolic) outcomes is now
warranted.
There remain however several unanswered questions relating to
brain energy metabolism and the role of ketones being used as an en-
ergy source promoting cognitive health. The effective dose and trial
duration required of such a MCT ketogenic drink to optimize benefits
on cognitive outcomes remains to be determined. Finally, it should be
investigated whether other approaches established to produce changes
in brain energy metabolism, such as caffeine (Vandenberghe et al.,
2017) or exercise (Castellano et al., 2017), should also be incorporated
into such an intervention, or whether this intervention should be part of
a multi-nutrient approach to mitigating neurodegenerative disease
progression.
3.5. Novel brain models
The broad availability of human stem cells, especially of induced
pluripotent stem cells (iPSC), has prompted the development of a
number of human brain organoid models. They come with different
advantages and disadvantages as to size, standardization, reflection of
anatomy and physiology and costs. The use of iPSC allows using dif-
ferent genetic backgrounds or iPSC lines, which were genetically
modified (isogenic cell lines), for example carrying certain risk or re-
porter genes. As the model reflects the developing brain, it has obvious
uses for developmental neurotoxicity (Hartung et al., 2017; Pamies
et al., 2018; Smirnova and Hartung, 2018), such as studies for causes
and treatments of autism.
In the context of the ageing brain, a number of brain diseases of the
elderly have been investigated using this approach. Based on the
finding that Alzheimer patient’s iPSC allow the generation of neurons
showing some hallmarks of the disease (Israel et al., 2012; Muratore
et al., 2014), such mini-brain models have started to be produced. Si-
milarly, a number of iPSC lines from patients with amyotrophic lateral
sclerosis have been employed to produce and compare the respective
mini brains, which is currently expanded to a larger number of donors.
Parkinson Disease is typically studied in animals treated with sub-
stances selectively destroying dopaminergic neurons but has since been
successfully translated to mini-brain models using substances such as
MPTP, its active metabolite MPP+or hydroxy-dopamine. In conclu-
sion, a number of neurodegenerative diseases typically affecting the
elderly can be modelled with brain and other organoid models derived
from human stem cells. Altogether, the mini-brain models represent a
versatile tool for brain research in various settings, allowing for re-
search not previously possible with rodents, and allowing examination
of disease models prior to clinical investigations in humans.
4. Shortcomings and future directions
There remain several significant shortcomings in nutrition research
focusing on candidate nutrients or dietary patterns which need to be
addressed in future investigations. A focus on improving the accuracy
and validity of dietary biomarkers is required in order to quantify
intake and measure change following a dietary intervention to establish
dose-dependent causality between intake and health outcomes. Current
estimates of dietary intake are dependent on food frequency ques-
tionnaires, which rely on published food composition data. In addition
to limitations related to self-report instruments (Archer et al., 2013;
Yuan et al., 2017), the high variability in food composition, for example
even within fruit taken from the same plant (Kuhnle, 2018; Wilkinson
and Perring, 1961), makes it very difficult to estimate intakes of certain
nutrients from whole foods, and instead mean values of nutritive
compounds are often taken to estimate dietary intakes. Methods of
preparation of certain foods can also affect composition, for example
the length of brewing time of tea can significant affect the availability
of flavan-3-ols (Fernando and Soysa, 2015). Biochemical markers of
dietary intake overcome the issues of imprecise measurement and
variability in food composition, as they rely instead on compounds that
have actually been extracted by the body (Kuhnle, 2012) (see section
1.3.5). As previously discussed, future research should continue to ex-
plore the utility of biomarkers whilst ensuring that their use is validated
against up-to-date published criteria.
Previous studies investigating the impact of specific nutrients or
combinations of nutrients on health may not have adequately targeted
populations that would benefit most from these interventions. Subjects
that have sufficient or high levels of certain nutrients at baseline may
not benefit in the same way from these approaches as those who are
deficient or have lower levels of candidate nutrients, and as such results
from studies grouping people regardless of baseline status may lead to
milder and non-significant associations. Furthermore, targeting older
adults in the prodromal stages of neurodegeneration, when they may be
more susceptible to prevention approaches, could produce more robust
results compared to focusing on healthy older adults or individuals
living with more pronounced conditions where the stage of atrophy
within the brain does not allow for significant improvements to be
observed. It may be possible to identify an optimal intervention time
point or window or set of conditions where benefits are most likely to
be observed. Clinical trials are continually aiming to target earlier
stages in the disease process to maximise benefits, which corresponds
with improvements in detection of disease leading to earlier diagnosis.
However, it remains unclear how early in the disease process treatment
would be feasible.
It is prudent to acknowledge that there is increasing concern re-
garding the selection of valid, reliable and sensitive cognitive and
neuropsychological assessments and the associated practice and pro-
cedures utilized to assess nutritional effects on the ageing brain. Some
authors have drawn attention to growing distrust of the findings ema-
nating from industry-academia collaborations (Fabbri et al., 2017;
Katan, 2007; Lesser et al., 2007; Nestle, 2016). The research community
needs to address these concerns and ensure the integrity of the research
outputs. There are clear indications of data dredging and p-hacking
(Simmons et al., 2011), which are particularly relevant to neu-
ropsychological tests where there are often multiple outcome measures
for individual tests (e.g. speed of response, accuracy). Numerous stra-
tegies have been employed to analyse these outcomes and some authors
combine individual test outcomes into factor scores or composite
measures of a purported cognitive domain which could increase the
likelihood of a significant effect. The ease with which computerized
cognitive batteries can now be designed and implemented is con-
tributing to greater diversity in measures of cognition, and therefore,
reduced standardization of procedures. This reduces comparability of
findings between studies, which can give the impression of lack of co-
herent effects. There is an obvious way to tackle these concerns; in-
crease replication and address the so-called reproducibility crisis
(Maxwell et al., 2015; Sorkin et al., 2016). However, this is hampered
by the pressure to attain to novel, marketable outcomes. There is also
evidence of ‘harking’ – the practice of hypothesizing findings post data-
analysis (Munafò et al., 2017). Furthermore, when hypothesized effects
are not observed, and null outcomes are reported, publication is
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significantly less likely. Moreover, even amongst published findings,
there is evidence of selection bias within systematic reviews (Walfisch
et al., 2013). If we are to establish a robust evidence base to support
nutritional benefits for the ageing brain then the need to pre-register
trials with clearly defined hypotheses, explicit outcome measures
(particularly with regards to cognitive function), and most importantly,
an a priori statistical analysis plan is crucial. For example, an analysis of
cognitive function should include pre-intervention baseline data as a
covariate since baseline performance or biological state is the strongest
predictor of subsequent response. Such an approach will also permit
examination of the interaction of baseline measures with nutritional
interventions. For example, breakfast interventions in children have
been shown to confer greatest benefit to children whose baseline per-
formance is average or less (Adolphus et al., 2017). Such interactions
likely also exist in ageing adults. This also highlights the importance of
considering characteristics which could influence cognitive perfor-
mance, such as socio-economic status, IQ, habitual diet, and physiolo-
gical/metabolic characteristics such as obesity and which if not, taken
into account represent residual confounders (Adolphus et al., 2017).
Indeed, guidance has been published on evaluating the integrity and
strength of evidence (JPT, H. and S, G., 2008), and many resources exist
for encouraging best working and research practices in nutrition and
health (e.g. (Alexander et al., 2015; Goldacre, 2017; Ioannidis, 2005;
Welch et al., 2011)). It would serve our field well to adhere to these
recommendations. Taking these steps is likely to increase confidence in
the veracity of the research, irrespective of funding source, for all sta-
keholders, including academics, industry, journalists, and the public.
Furthermore, with increasing pressure to identify and implement
strategies that prevent neurodegenerative disease in the context of an
ageing population and the considerable personal and financial cost of
these conditions, there is a corresponding pressure placed on those in
the scientific community to communicate recommendations based on
these investigations to the general public and policy-makers in a way
that is convincing and accessible. However, within the European Union
(EU) there are strict conditions on the use of health claims also in re-
lation to cognition. The legal framework for making health claims
within the EU is contained within the Regulation on Food Information
for Consumers (FIC) (Regulation (EU) No 1169/20114) and in the
Claims Regulation (Regulation (EC) No 1924/20065). These regulations
are in place to ensure that information pertaining to food or nutrients
are not misleading or attribute them affects which are not supported by
sufficient evidence. In addition to ensuring information pertaining to
food is clear and understandable; the FIC prohibits medical claims to be
made relating to food products, which includes claims targeting the
prevention or treatment of a particular disease in humans. In a similar
vein, the Claims Regulation defines a health claim as a voluntary
message in any form that states or suggests that a food has particular
characteristics. In fact, claims should be linked to particular nutrients
contained in food products, regarding which it has been shown they
have a beneficial effect to human health. These claims include general
health claims, health claims targeting children, and disease-risk re-
duction claims. Cognitive health claims, just like any type of health
claim, can only be made regarding a particular food product provided
that it has been shown to have a beneficial nutritional or physiological
effect, the active nutrient is present in the end product which will
produce the claimed effect, and it is present in a form that is bioa-
vailable to the human body. Active ingredients for which so far health
claims in relation to cognitive function have been authorized are zinc,
copper and iodine. An example of such authorized claim is “zinc con-
tributes to a regular problem-solving ability”. The Claims Regulation does
not apply to purely scientific (i.e. non-commercial) communications,
such that evidence-based results regarding specific bioactive nutrients
or foods can be communicated provided that there is no direct link to
commercial interests. This is different however when communications
are targeted at health care professionals, that might end up with the
consumer as well. The European Court of Justice has clarified in a 2016
decision6 that in such context, the Claims Regulation applies as well.
Finally, there remains the obstacle of moving from evidence to
implementation of these findings in clinical and public health settings.
In the absence of current pharmacological interventions to delay or stop
the progression of neurodegenerative disease, a combination of drug
and lifestyle interventions appear to be a promising avenue of curtailing
the disease processes underlying age-related cognitive decline
(Kivipelto et al., 2013; Lombardo, 2012; Martinez-Lapiscina et al.,
2013; Morris et al., 2015b; Ngandu et al., 2015; Psaltopoulou et al.,
2013; Scarmeas et al., 2006; Valls-Pedret et al., 2015). However, par-
ticularly in the context of care homes and services provided specifically
to older adults, the adoption of such lifestyle interventions could be
costly and would require not only a sound evidence base of the efficacy
of certain nutritional and dietary changes, but also practical examples
of how these changes can be implemented in a way that is both eco-
nomical and of optimal benefit to service users in order to ensure these
practice are adopted. Indeed, there are such practices emerging in the
USA such as the Memory Preservation Nutrition (MPN) program de-
veloped by medical practitioners and researchers at Boston University
School of Medicine and Tufts University School of Medicine (Emerson
Lombardo et al., 2006; Wolf et al., 2012). The MPN implements six key
principles including 1) increasing the amount and variety of anti-oxi-
dative nutrients such as vitamin E, vitamin C and β-carotenes (Morris
et al., 2002), 2) reducing insulin resistance, 3) reducing LDL cholesterol
and avoid trans fats and reduce sugar intake, 4) increasing omega-3
fatty acids and other healthy fats (Okereke et al., 2012) 5) reducing
inflammation, and 6) assuring adequate B, C, D, and E vitamins
(Kivipelto et al., 2008; Morris et al., 2004, 2005). The MPN program is
also updated in line with emerging evidence (Jacka et al., 2017;
Parletta et al., 2019) and an additional 7th principle focusing on in-
creasing prebiotic and probiotic intake has been included since 2017. In
general, increasing intake of fermented foods including pickled vege-
tables, leafy greens (e.g. sauerkraut, kimchi), fermented dairy as the
preferred form of dairy, and various foods basic to some ethnic diets
such as miso, soy or tempeh are recommended. With the aid of die-
titians, nutritionists, and educators this program has begun to be im-
plemented in a number of senior residences and programs targeting
older adults, as well as individuals across the lifespan. As lifestyle and
dietary changes can be challenging to implement, the MPN provides
guidelines for adoption of this program by individuals and care provi-
ders by including detailed guides, recipes, shopping lists, progress
monitoring and coaching (for example see7,8,9). These practices have
begun to be adopted by service providers in the USA. Although the
long-term benefits of such practices remain to be determined, programs
such as MPN are an example of possible implementation of life-style
changes, demonstrating that putting them into practice has the poten-
tial to be practical and feasibly adopted by both service providers and
recipients.
5. Conclusions
Lifestyle approaches to combatting the growing burden of age-
4 Regulation (EU) no 1169/2011 of the European Parliament and of the
Council of 25 October 2011on the provision of food information to consumers.
5 Regulation (EC) No 1924/2006 of the European Parliament and of the
Council of 20 December 2006 on nutrition and health claims made on foods.
6 Judgment of the Court (Third Chamber). 14 July 2016.
7 Emerson Lombardo NB (Nov 2014) Brain Healthy Foods for the Holidays.
Acton, MA: Brain Health and Wellness Center®
8 Emerson Lombardo NB. (Nov 2015) Brain Healthy Foods: Menus and
Recipes Vol. 1. Acton, MA: Brain Health and Wellness Center®.
9 http://brainwellness.com/
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related neurodegeneration is receiving increased attention, and the
evidence for the impact of diet on disease processes that contribute to
pathological brain ageing shows particular promise. Although certain
nutrients such as omega-3 fatty acids, flavonoids and B vitamins have
been found to impact disease mechanisms underlying cognitive ageing,
in light of findings from large-scale observational studies suggesting a
complex interplay between nutrients and their impact on health, the
focus on the beneficial health effects of specific nutrients has shifted
towards multi-nutrient and whole diet approaches to improving brain
health.
New avenues for exploring the role of diet in healthy ageing have
emerged in recent years, and particularly the impact of the gut micro-
biome and its manipulation by certain dietary factors, including pro-
biotics and postbiotics, is accumulating promising evidence for the
promotion of healthy host brain ageing and general longevity.
However, there remain unanswered questions regarding how the im-
pact of the gut microbiome is regulated by diet and its mechanisms of
action.
The emergence of new techniques such as imaging measures of
brain metabolism, metabolomics and improved measurement of ageing
and dietary biomarkers, and novel brain modelling techniques are en-
abling researchers to approach finding answers to these questions.
Improvements in the way we are able to measure the direct relationship
between whole food nutrient composition and its impact on health and
how this impact changes across different populations and age groups
will aid in determining optimal approaches to improving brain health
with diet across the lifespan, particularly cognitive ageing as measured
by improved neuropsychological tests and their analysis.
Implementation of large-scale preventive interventions based on
dietary patterns identified as being beneficial to brain health should be
a research and public health priority, ideally in conjunction with other
health-promoting lifestyle factors.
There is an increasing societal interest in how lifestyle factors can be
modified to prevent cognitive decline and generally improve health
over the lifespan. However, there exists an overwhelming amount of
inaccurate and conflicting information available from media including
the internet, which can often drown out evidence-based recommenda-
tions for improving and maintaining health. In light of this, a more
robust, accessible, and convincing repository of information regarding
how to improve health needs to be made available to the public, while
still complying with guidelines and laws pertaining to health claims.
The ultimate aim of this research is to translate these findings into
clinical and public health contexts, and indeed early evidence-based
programs being currently implemented in aged care settings have
shown particular promise. However, further investigation to improve
our understanding of the mechanisms by which nutrition can improve
brain health across the human lifespan is still required.
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